Insider · CIK 0002064348
Yanina Grant-Huerta
Files at ATRA (Atara Biotherapeutics, Inc.). First filing May 20, 2025, latest Nov 19, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATRA: Atara Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Atara Biotherapeutics, Inc. | $24k 1,804 shares | -5% | +147% from low-27% from high | |
| 23Weak | Atara Biotherapeutics, Inc. | $21k 1,809 shares | -5% | +117% from low-36% from high | |
| 23Weak | Atara Biotherapeutics, Inc. | $15k 2,218 shares | -6% | +29% from low-62% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -1,645 | $13.19 | $22k | 33,613 | Nov 19, 2025 |
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -85 | $13.19 | $1,121 | 33,528 | Nov 19, 2025 |
| Nov 17, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -74 | $13.19 | $976 | 33,454 | Nov 19, 2025 |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -55 | $11.61 | $639 | 37,012 | Aug 20, 2025 |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -86 | $11.61 | $999 | 36,926 | Aug 20, 2025 |
| Aug 18, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -1,668 | $11.61 | $19k | 35,258 | Aug 20, 2025 |
| May 16, 2025 | ATRA Atara Biotherapeutics, Inc. | SOpen-market sale Common Stock | -2,218 | $6.76 | $15k | 37,067 | May 20, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.